Table 5.
Impact of preoperative exclusive enteral nutrition on surgical outcomes
| Authors | EEN/no-EEN patients, n | Morbidity, % |
Uni- variate analysis, P | Multivariate analysis | Anastomotic leak, % |
Univariate analysis, P | Stoma rate, % |
Uni- variate analysis, P | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EEN patients | no-EEN patients | EEN patients | no-EEN patients | EEN patients | no-EEN patients | ||||||
| Li et al. [57] | 219*/332†, 29‡, 128 § | Infectious - 18.7*/ non-infectious - 7.8* | Infectious - 51.7 ‡ 28.9 † / non-infectious - 31 †, 15.6 ‡ | <0001/ <0.001 | OR - 0.53 II / OR - 0.35 II | 4.1* | 17.2† 10.2‡ 3§ |
<0.05† <0.05‡ ns§ |
17.8* | 65.5† 34.4‡ 22§ |
<0.001† <0.05‡ ns§ |
| Heerasing et al. [58] | 38/76 | Global - 8/ anastomotic leak or abscesses - 3 | Global - 32/ anastomotic leak or abscess - 20 | <0.001/ 0.019 | –/OR - 9.1** | N/R | N/R | − | 3 | 8 | ns |
| Beaupel et al. [59] | 35/21 | Global - 22.9/ ASCs - 14.3 | Global - 23.8/ ASCs - 23.8 | ns | − | 2.8 | 0 | ns | 11.4 | 0 | ns |
| Zhu et al. [60] | 46/28 | IASCs - 6.5 | IASCs - 25 | 0.036 | − | N/R | N/R | - | 43.5 | 46.4 | ns |
EEN, exclusive enteral nutrition; OR, odds ratio; N/R, not reported; ASCs, abdominal septic complications; IASCs, intraabdominal septic complications.
*
Group 4 - preoperative EEN and immunosuppressant-free interval (CSTs, immunomodulators, and biologics) less than 8 weeks.
†
Group 2 - immunosuppressant therapy at surgery.
‡
Group 3 - preoperative immunosuppressant-free interval less than 8 weeks.
§
Group 1 - preoperative immunosuppressant-free interval more than 8 weeks.
II
OR - likelihood of EEN patients having infectious and non-infectious complications, respectively.
**
OR - likelihood of EEN patients not having anastomotic dehiscence or abscess.